



European Heart Journal Supplements

Volume 10 Supplement C April 2008

Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit <i>A.G.G. Turpie</i>	C1
Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention <i>J.W. Eikelboom</i>	C8
Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes <i>S.R. Mehta</i>	C14
The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes <i>J.-P. Bassand</i>	C22